Enhanced Bilayer Tablets with Improved Stability and Dissolution

The present inventive concept relates to improved bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, with enhanced stability and dissolution properties, achieved through the incorporation of pH-dependent polymers, dissolution aids, and optimized layer compositions.

The original patent disclosed bilayer tablets with acetylsalicylic acid and pseudoephedrine, but these tablets had limitations in terms of stability and dissolution rates. The present inventive concept addresses these limitations by introducing novel components and layer configurations that improve the overall performance of the tablets.

The new claims describe a system for bilayer tablets comprising a dissolution aid layer with a pH-dependent polymer and a dissolution aid, which maintains a pH of 6.5 or higher during dissolution. The acetylsalicylic acid layer comprises granules with intragranular acetylsalicylic acid, intragranular sodium carbonate, and one or more intragranular excipients. The inventive concept also encompasses methods for preparing bilayer tablets with optimized layer compositions and coatings, as well as a packaging system that minimizes exposure to moisture. Additionally, the inventive concept includes a bilayer tablet with an acetylsalicylic acid layer and a pseudoephedrine layer comprising a mixture of pseudoephedrine and a stabilizer, such as antioxidants or chelating agents.

The new claims introduce the use of pH-dependent polymers and dissolution aids, which provide a novel solution to the stability and dissolution limitations of the original patent. The optimized layer compositions and coatings, as well as the packaging system, also contribute to the inventive step of the present concept.

Alternative embodiments of the inventive concept could include the use of different pH-dependent polymers or dissolution aids, varying the composition of the acetylsalicylic acid and pseudoephedrine layers, or incorporating additional active pharmaceutical ingredients. The inventive concept could also be adapted for use with different types of tablets or dosage forms.

The enhanced bilayer tablets with improved stability and dissolution properties have significant commercial potential in the pharmaceutical industry, particularly for the treatment of cold and flu symptoms. The inventive concept could be marketed as a premium product with improved performance and shelf life, targeting patients and healthcare professionals seeking more effective and convenient treatment options.